Where is the article on Amgen? It's not in the WSJ
Stan, I have the most recent Credit Suisse rpt on AMGN, its about 54 pages. If you want it I'll e-mail it to do. Its rated underperform with a price target of $65 Respond to firstname.lastname@example.org
UBS analyst left the company, no bio coverage pending reasignment.
Stan, your medical knowledge and insight are impressive. I'm curious, what is your background and profession? zI've been an investor in Amgen since 1986 when the company was doing trials on EPO. Best Regards